Wellstein A, Palm D, Belz G G
J Cardiovasc Pharmacol. 1986;8 Suppl 11:S36-40. doi: 10.1097/00005344-198511001-00006.
The potency order of the catecholamines (-)-isoprenaline (Iso), (-)-noradrenaline (NA), and (-)-adrenaline (Adr) in competition for radiolabelled sites is used for their pharmacological classification. It is shown that the radioligand 3H-CGP 12177 exclusively labels beta 1-adrenoceptors in rat salivary gland membranes (Iso greater than NA greater than Adr), and beta 2-adrenoceptors in rat reticulocytes (Iso greater than Adr greater than or equal to NA). These models are then used to derive the subtype-selectivity of the classical beta-adrenoceptor antagonists (+/-)-propranolol (prop; twofold beta 2-selective) and (+/-)-atenolol (aten; 35-fold beta 1-selective), as well as of the newer antagonists (+/-)-betaxolol and (+/-)-bisoprolol (betax and biso; 35-fold and 75-fold beta 1-selective, respectively). The ligand with the highest selectivity is ICI 118,551 (ICI), with a 300-fold beta 2-subtype selectivity. For comparison with antagonistic effects in humans at given plasma concentrations, the equilibrium dissociation constants of the ligands are measured in the presence of native human plasma and yield values for the relative selectively labelled subtype in the mean (Ki-values in nmol/l): prop: 20, aten: 250, biso: 24, betax: 23, and ICI: 2.5.
儿茶酚胺(-)-异丙肾上腺素(Iso)、(-)-去甲肾上腺素(NA)和(-)-肾上腺素(Adr)竞争放射性标记位点的效价顺序用于它们的药理学分类。结果表明,放射性配体3H-CGP 12177专门标记大鼠唾液腺膜中的β1-肾上腺素能受体(Iso>NA>Adr)以及大鼠网织红细胞中的β2-肾上腺素能受体(Iso>Adr≥NA)。然后利用这些模型推导经典β-肾上腺素能拮抗剂(±)-普萘洛尔(prop;对β2有两倍选择性)、(±)-阿替洛尔(aten;对β1有35倍选择性)以及新型拮抗剂(±)-倍他洛尔和(±)-比索洛尔(betax和biso;分别对β1有35倍和75倍选择性)的亚型选择性。选择性最高的配体是ICI 118,551(ICI),对β2亚型有300倍选择性。为了与给定血浆浓度下在人体中的拮抗作用进行比较,在天然人血浆存在的情况下测量配体的平衡解离常数,并得出平均相对选择性标记亚型的值(Ki值,单位为nmol/l):prop:20,aten:250,biso:24,betax:23,ICI:2.5。